CNS Cancers

Novel Glioblastoma Treatment Granted Orphan Drug Designation

Moleculin Biotech announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to WP1066 for the treatment of glioblastoma. WP1066 is an immuno-stimulating STAT3 (signal transducers and activators of transcription) inhibitor being investigated as a potential treatment for brain tumors, pancreatic cancer, and acute myeloid leukemia. In preclinical models, the inhibition of…

Sex Differences ID’d in Response to Glioblastoma Treatment

HealthDay News — Sex differences have been identified in response to therapy among glioblastoma (GBM) patients, according to a study published in the January 2 issue of Science Translational Medicine. Wei Yang, PhD, from the Washington University School of Medicine in St. Louis, and colleagues used a quantitative image-based measure of response to examine the…

NIH Releases Large-Scale Dataset of CT Images

Unlike most lesion medical image datasets currently available, which can detect only 1 type of lesion, DeepLesion has much diversity and contains critical radiology findings from across the body, including lung nodules, liver tumors, and enlarged lymph nodes.

Afinitor Disperz Approved to Treat TSC-Associated Partial-Onset Seizures

The approval was based on the Phase 3, randomized, double-blind, placebo-controlled EXIST-3 (EXamining everolimus In a Study of TSC) study which evaluated adjunctive Afinitor Disperz (low exposure: 3-7ng/mL; high exposure: 9-15ng/mL) in patients with treatment-resistant TSC-associated partial-onset seizures, defined as inadequate control of partial-onset seizures despite use of ≥2 sequential regimens of single or combined anti-epileptic drugs.